__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
PIQRAY® is given in combination with fulvestrant.1
Dosing and administration1
Continue treatment until disease progression or until unacceptable toxicity occurs.
*Tablets should not be chewed, crushed or split prior to swallowing. No tablet should be ingested if it is broken, cracked, or otherwise not intact.
Accounting for missed PIQRAY® doses1
- If a dose is missed, it can be taken immediately following food and within 9 hours after the time it is usually administered. After more than 9 hours, the dose should be skipped for that day. The next day, PIQRAY® should be taken at its usual time
- If the patient vomits after taking the dose, the patient should not take an additional dose on that day, and should resume the usual dosing schedule the next day at the usual time
Certain AEs may require dose modifications1
THERAPY MANAGEMENT GUIDE
Please see the therapy management guide for more details on dosing and administration.
The blister pack is designed to help patients stay on track with treatment1
AE, adverse event.
Reference
- PIQRAY® (alpelisib) Summary of Product Characteristics. Novartis Pharma; December 2021.
Rate this content:
UK | April 2022 | 186029